Skip to main content

22 Activity of the tumor-intrinsic NLRP3 inflammasome pathway predicts for response to checkpoint inhibitor immunotherapy in melanoma patients

Publication ,  Conference
Haykal, T; Yarla, N; DeVito, N; Beasley, G; Salama, A; Hanks, B; Theivanthiran, B
Published in: Regular and Young Investigator Award Abstracts
November 2022

Duke Scholars

Published In

Regular and Young Investigator Award Abstracts

DOI

Publication Date

November 2022

Publisher

BMJ Publishing Group Ltd

Conference Name

SITC 37th Annual Meeting (SITC 2022) Abstracts

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Haykal, T., Yarla, N., DeVito, N., Beasley, G., Salama, A., Hanks, B., & Theivanthiran, B. (2022). 22 Activity of the tumor-intrinsic NLRP3 inflammasome pathway predicts for response to checkpoint inhibitor immunotherapy in melanoma patients. In Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd. https://doi.org/10.1136/jitc-2022-sitc2022.0022
Haykal, Tarek, Nagendra Yarla, Nicholas DeVito, Georgia Beasley, April Salama, Brent Hanks, and Balamayooran Theivanthiran. “22 Activity of the tumor-intrinsic NLRP3 inflammasome pathway predicts for response to checkpoint inhibitor immunotherapy in melanoma patients.” In Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd, 2022. https://doi.org/10.1136/jitc-2022-sitc2022.0022.
Haykal T, Yarla N, DeVito N, Beasley G, Salama A, Hanks B, et al. 22 Activity of the tumor-intrinsic NLRP3 inflammasome pathway predicts for response to checkpoint inhibitor immunotherapy in melanoma patients. In: Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2022.
Haykal, Tarek, et al. “22 Activity of the tumor-intrinsic NLRP3 inflammasome pathway predicts for response to checkpoint inhibitor immunotherapy in melanoma patients.” Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, 2022. Crossref, doi:10.1136/jitc-2022-sitc2022.0022.
Haykal T, Yarla N, DeVito N, Beasley G, Salama A, Hanks B, Theivanthiran B. 22 Activity of the tumor-intrinsic NLRP3 inflammasome pathway predicts for response to checkpoint inhibitor immunotherapy in melanoma patients. Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2022.

Published In

Regular and Young Investigator Award Abstracts

DOI

Publication Date

November 2022

Publisher

BMJ Publishing Group Ltd

Conference Name

SITC 37th Annual Meeting (SITC 2022) Abstracts

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3204 Immunology